Menu Search
Equities

Auscann Group Holdings Ltd

ACNNF:PKC

Auscann Group Holdings Ltd

Actions
  • Price (USD)0.005
  • Today's Change0.00 / 0.00%
  • Shares traded10.36k
  • 1 Year change+138.10%
  • Beta--
Data delayed at least 15 minutes, as of May 28 2024 17:46 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AusCann Group Holdings Limited is an Australia-based company focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. It has launched tetrahydrocannabinol and cannabidiol (THC/CBD) powder-based hard-shell capsules, based on the Company’s Neuvis platform, for the treatment of pain and related indications. Its products include CPAT-01, DermaCann and MicroMax. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol (THC) and cannabinoids (CBD) whole plant extracts in a proprietary ratio to target pain and inflammation in dogs. DermaCann is a CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. The product is a liquid oral oil formulation containing CBD in a patented combination with other bioactive lipids designed to target inflammation and immune modulation pathways.

  • Revenue in AUD (TTM)2.05m
  • Net income in AUD-9.44m
  • Incorporated1986
  • Employees27.00
  • Location
    Auscann Group Holdings LtdWangaraPO Box 1746PERTH 6947AustraliaAUS
  • Phone+61 86305-0705
  • Fax+61 39909-7585
  • Websitehttps://auscann.com.au/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.